1. A PHASE II TRIAL OF REDUCED DOSE BRENTUXIMAB VEDOTIN FOR CUTANEOUS T‐CELL LYMPHOMAS. (17th June 2021) Authors: Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; Ganesan, N.; Sohail, S.; Santarosa, A.; Galasso, N.; Kim, E.; Myskowski, P.; Kim, Y. H.; Horwitz, S.; Moskowitz, A. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Development, Characterization, and Evaluation of SLN-Loaded Thermoresponsive Hydrogel System of Topotecan as Biological Macromolecule for Colorectal Delivery. (5th July 2021) Authors: Xing, R.; Mustapha, O.; Ali, T.; Rehman, M.; Zaidi, S. S.; Baseer, A.; Batool, S.; Mukhtiar, M.; Shafique, S.; Malik, M.; Sohail, S.; Ali, Z.; Zahid, F.; Zeb, A.; Shah, F.; Yousaf, A.; Din, F. Other Names: Di Stefano Luisa Academic Editor. Journal: BioMed research international Issue: Volume 2021(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Frequency and causes of deferral amongst voluntary non‐remunerated blood donors from Pakistan – a single‐centre study. (2nd February 2018) Authors: Jamal, S.; Shaikh, I.; Sohail, S.; Ata, U.; Ali, A.; Saleem, S. Journal: ISBT science series Issue: Volume 13:Number 2(2018) Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗